Sichuan Goldstone Asia Pharmaceutical (SZSE:300434) Net Income From Continuing Operations : ¥68 Mil (TTM As of Mar. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Sichuan Goldstone Asia Pharmaceutical Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Sichuan Goldstone Asia Pharmaceutical's net income from continuing operations for the three months ended in Mar. 2024 was ¥90 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Mar. 2024 was ¥68 Mil.

Sichuan Goldstone Asia Pharmaceutical Net Income From Continuing Operations Historical Data

The historical data trend for Sichuan Goldstone Asia Pharmaceutical's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sichuan Goldstone Asia Pharmaceutical Net Income From Continuing Operations Chart

Sichuan Goldstone Asia Pharmaceutical Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Income From Continuing Operations

Get a 7-Day Free Trial

125.87

-684.48

66.10

213.05

120.71

Sichuan Goldstone Asia Pharmaceutical Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Net Income From Continuing Operations	Get a 7-Day Free Trial															142.50	11.24	-18.24	-14.78	89.54

Sichuan Goldstone Asia Pharmaceutical Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥68 Mil.

Sichuan Goldstone Asia Pharmaceutical (SZSE:300434) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Industrials » Industrial Distribution » Sichuan Goldstone Asia Pharmaceutical Inc (SZSE:300434) » Definitions » Net Income From Continuing Operations

Comparable Companies

Traded in Other Exchanges

N/A

Address

8 Jiayuan Road, 8th Floor, District A1, Dadi Xinguanghua Plaza, Chengdu, CHN, 610072

Website

http://www.goldstone-group.com

Sichuan Goldstone Asia Pharmaceutical Inc is engaged in development and application of steel-reinforced plastic composite pipe technology, providing customers with steel-reinforced plastic composite pipes from pipe structure, production process to construction technology. The company is also engaged in research and development, production and sales of medicines and health products.

Sichuan Goldstone Asia Pharmaceutical (SZSE:300434) Headlines

No Headlines